Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review

Rheumatology (Oxford). 2021 Oct 2;60(10):4530-4537. doi: 10.1093/rheumatology/keab026.

Abstract

Objective: To better define the clinical distinctions between the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related paediatric inflammatory multisystem syndrome (PIMS) and Kawasaki disease (KD).

Methods: We compared three groups of patients: group 1, cases from our national historic KD database (KD-HIS), before the SARS-CoV-2 pandemic; group 2, patients with KD admitted to an intensive care unit (KD-ICU) from both our original cohort and the literature, before the SARS-CoV-2 pandemic; and group 3, patients with PIMS from the literature.

Results: KD-HIS included 425 patients [male:female ratio 1.3, mean age 2.8 years (s.d. 2.4)], KD-ICU 176 patients [male:female ratio 1.3, mean age 3.5 years (s.d. 3.1)] and PIMS 404 patients [male:female ratio 1.4, mean age 8.8 years (s.d. 3.7)]. As compared with KD-HIS patients, KD-ICU and PIMS patients had a higher proportion of cardiac failure, digestive and neurological signs. KD-ICU and PIMS patients also had a lower frequency of typical KD-mucocutaneous signs, lower platelet count, higher CRP and lower sodium level. As compared with KD-HIS and KD-ICU patients, PIMS patients were older and more frequently had myocarditis; they also had fewer coronary abnormalities and lower sodium levels. Unresponsiveness to IVIG was more frequent in KD-ICU than KD-HIS and PIMS patients.

Conclusion: On clinical grounds, KD-HIS, KD-ICU and PIMS might belong to a common spectrum of non-specific pathogen-triggered hyperinflammatory states. The causes of increasing inflammation severity within the three entities and the different effects on the heart remain to be determined.

Keywords: COVID-19; Kawasaki disease; PIMS/MIS-C; SARS-CoV-2-related inflammatory multisystem syndrome; intensive care unit; intravenous immunoglobulins; shock syndrome; systemic vasculitis.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Aspirin / therapeutic use
  • C-Reactive Protein / metabolism
  • COVID-19 / blood
  • COVID-19 / physiopathology*
  • COVID-19 / therapy
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Coronary Disease / physiopathology*
  • Digestive System Diseases / physiopathology
  • Female
  • France
  • Glucocorticoids / therapeutic use
  • Heart Failure / physiopathology*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Infant
  • Infant, Newborn
  • Intensive Care Units, Pediatric
  • Male
  • Mucocutaneous Lymph Node Syndrome / blood
  • Mucocutaneous Lymph Node Syndrome / physiopathology*
  • Mucocutaneous Lymph Node Syndrome / therapy
  • Myocarditis / blood
  • Myocarditis / physiopathology*
  • Nervous System Diseases / physiopathology
  • Pericardial Effusion / physiopathology*
  • Phenotype
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Count
  • Sodium / blood
  • Systemic Inflammatory Response Syndrome / blood
  • Systemic Inflammatory Response Syndrome / physiopathology*
  • Systemic Inflammatory Response Syndrome / therapy
  • Ventricular Dysfunction, Left / physiopathology*
  • Ventricular Dysfunction, Right / physiopathology*

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Platelet Aggregation Inhibitors
  • C-Reactive Protein
  • Sodium
  • Aspirin

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related